Jordi Riera, Chief Business Development Manager Kaneka Probiotics, detailed two studies utilizing precision probiotics. The first study focused on probiotic strains on two L. plantarum strains as well as P. acidilactici, which were shown to produce postbiotic molecules including acetate, polyP, ACh and antimicrobial compounds (potentially bacteriocins) against IBS-associated microorganisms. This unique combination of postbiotics could explain the clinically beneficial effects of the probiotic mix in IBS subjects.
“The mechanisms achieved are significant results in IBS quality of life,” said Riera. “The key takeaway is that the customers that took the product really notice the effects.”
Riera also detailed another Kaneka study that assessed the efficacy of probiotics in improving lactose intolerance symptoms compared with placebo after 8 weeks of treatment. The probiotic blend i3.1 is a blend that contains three live strains - Pediococcus acidilactici CECT 7483, Lactobacillus plantarum CECT 7484 and Lactobacillus plantarum CECT 7485.
“Symptoms of lactose intolerance are very close to IBS, same discomfort, diarrhea, anxiety, and bad quality of life and that one achieved positive results.” Riera added that the probiotics were effective in reducing lactose intolerance symptoms.
Kaneka also has more research in the pipeline, with an exciting new study that will be disclosed soon. “I can tell you that it will be the world's first probiotic with a clinical trial on menopause," Riera said. "Menopause is the next big issue.”
